Literature DB >> 30320205

Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection.

Pavimol Angsantikul1, Soracha Thamphiwatana1, Qiangzhe Zhang1, Kevin Spiekermann1, Jia Zhuang1, Ronnie H Fang1, Weiwei Gao1, Marygorret Obonyo2, Liangfang Zhang1.   

Abstract

Inspired by the natural pathogen-host interactions and adhesion, this study reports on the development of a novel targeted nanotherapeutics for the treatment of Helicobacter pylori (H. pylori) infection. Specifically, plasma membranes of gastric epithelial cells (e.g. AGS cells) are collected and coated onto antibiotic-loaded polymeric cores, the resulting biomimetic nanoparticles (denoted AGS-NPs) bear the same surface antigens as the source AGS cells and thus have inherent adhesion to H. pylori bacteria. When incubated with H. pylori bacteria in vitro, the AGS-NPs preferentially accumulate on the bacterial surfaces. Using clarithromycin (CLR) as a model antibiotic and a mouse model of H. pylori infection, the CLR-loaded AGS-NPs demonstrate superior therapeutic efficacy as compared the free drug counterpart as well as non-targeted nanoparticle control group. Overall, this work illustrates the promise and strength of using natural host cell membranes to functionalize drug nanocarriers for targeted drug delivery to pathogens that colonize on the host cells. As host-pathogen adhesion represents a common biological event for various types of pathogenic bacteria, the bioinspired nanotherapeutic strategy reported here represents a versatile delivery platform that may be applied to treat numerous infectious diseases.

Entities:  

Keywords:  active targeting; antimicrobial delivery; bacterial infection; biomimetic nanoparticle; nanomedicine

Year:  2018        PMID: 30320205      PMCID: PMC6176867          DOI: 10.1002/adtp.201800016

Source DB:  PubMed          Journal:  Adv Ther (Weinh)        ISSN: 2366-3987


  47 in total

Review 1.  Clinical practice. Helicobacter pylori infection.

Authors:  Kenneth E L McColl
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

Review 2.  Pathogenesis of Helicobacter pylori Infection.

Authors:  Dionyssios N Sgouras; Tran Thi Huyen Trang; Yoshio Yamaoka
Journal:  Helicobacter       Date:  2015-09       Impact factor: 5.753

Review 3.  Coating nanoparticles with cell membranes for targeted drug delivery.

Authors:  Weiwei Gao; Liangfang Zhang
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

Review 4.  Bacterial adhesion and entry into host cells.

Authors:  Javier Pizarro-Cerdá; Pascale Cossart
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

Review 5.  Antibiotic resistance in Helicobacter pylori.

Authors:  Claudio Alba; Ana Blanco; Teresa Alarcón
Journal:  Curr Opin Infect Dis       Date:  2017-10       Impact factor: 4.915

6.  Broad-Spectrum Neutralization of Pore-Forming Toxins with Human Erythrocyte Membrane-Coated Nanosponges.

Authors:  Yijie Chen; Mengchun Chen; Yue Zhang; Joo Hee Lee; Tamara Escajadillo; Hua Gong; Ronnie H Fang; Weiwei Gao; Victor Nizet; Liangfang Zhang
Journal:  Adv Healthc Mater       Date:  2018-02-13       Impact factor: 9.933

7.  Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori.

Authors:  Marygorret Obonyo; Li Zhang; Soracha Thamphiwatana; Dissaya Pornpattananangkul; Victoria Fu; Liangfang Zhang
Journal:  Mol Pharm       Date:  2012-08-06       Impact factor: 4.939

8.  Structural insights into Helicobacter pylori oncoprotein CagA interaction with β1 integrin.

Authors:  Burcu Kaplan-Türköz; Luisa F Jiménez-Soto; Cyril Dian; Claudia Ertl; Han Remaut; Arthur Louche; Tommaso Tosi; Rainer Haas; Laurent Terradot
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

9.  Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery.

Authors:  Soracha Thamphiwatana; Victoria Fu; Jingying Zhu; Diannan Lu; Weiwei Gao; Liangfang Zhang
Journal:  Langmuir       Date:  2013-09-16       Impact factor: 3.882

Review 10.  Taking it Personally: Personalized Utilization of the Human Microbiome in Health and Disease.

Authors:  Niv Zmora; David Zeevi; Tal Korem; Eran Segal; Eran Elinav
Journal:  Cell Host Microbe       Date:  2016-01-13       Impact factor: 21.023

View more
  19 in total

Review 1.  Engineering biological interactions on the nanoscale.

Authors:  Yao Jiang; Sanam Chekuri; Ronnie H Fang; Liangfang Zhang
Journal:  Curr Opin Biotechnol       Date:  2018-11-01       Impact factor: 9.740

Review 2.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

Review 3.  Generation, purification and engineering of extracellular vesicles and their biomedical applications.

Authors:  Jin Gao; Xinyue Dong; Zhenjia Wang
Journal:  Methods       Date:  2019-11-30       Impact factor: 3.608

Review 4.  Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy.

Authors:  Runqi Zhu; Tianqun Lang; Wenlu Yan; Xiao Zhu; Xin Huang; Qi Yin; Yaping Li
Journal:  Adv Sci (Weinh)       Date:  2021-03-09       Impact factor: 16.806

Review 5.  Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria.

Authors:  Bingqing Yang; Dan Fang; Qingyan Lv; Zhiqiang Wang; Yuan Liu
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 6.  Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials.

Authors:  Veena Vijayan; Adityanarayan Mohapatra; Saji Uthaman; In-Kyu Park
Journal:  Pharmaceutics       Date:  2019-10-14       Impact factor: 6.321

7.  Recent advances in cell membrane-camouflaged nanoparticles for inflammation therapy.

Authors:  Rongtao Zhang; Siqiong Wu; Qian Ding; Qingze Fan; Yan Dai; Shiwei Guo; Yun Ye; Chunhong Li; Meiling Zhou
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 8.  The role of gut microbiota in cancer treatment: friend or foe?

Authors:  Wing Yin Cheng; Chun-Ying Wu; Jun Yu
Journal:  Gut       Date:  2020-08-05       Impact factor: 23.059

Review 9.  Promising Recent Strategies with Potential Clinical Translational Value to Combat Antibacterial Resistant Surge.

Authors:  Partha Karmakar; Vishwanath Gaitonde
Journal:  Medicines (Basel)       Date:  2019-01-31

Review 10.  Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles.

Authors:  Vo Van Giau; Seong Soo A An; John Hulme
Journal:  Drug Des Devel Ther       Date:  2019-01-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.